Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

NCT01446900 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT01446900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01446900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Lead sponsor
European Institute of Oncology
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2011
Completion date
December 31, 2017
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia, small lymphocytic lymphoma